Samsung Pharm

Samsung Pharm is a long-standing South Korean pharmaceutical company founded in 1929, currently operating as a subsidiary of GEMVax & KAEL. The company specializes in the development and manufacturing of prescription drugs, over-the-counter medicines, and health functional foods. Its most notable recent development is Riavax (GV1001), a peptide-based immunotherapy targeting telomerase for the treatment of pancreatic cancer. Beyond oncology, the company is expanding its research into neurodegenerative diseases like Alzheimer's and other chronic conditions. Samsung Pharm maintains a diverse portfolio of legacy products while leveraging its parent company's biotech expertise to advance its clinical pipeline. The company is publicly traded on the Korea Exchange and operates significant manufacturing facilities in Hwaseong.